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1. ABSTRACT 
 
 4 
Introduction: Despite increased visibility of clinical trials through international trial 
registries, patients often remain uninformed of their existence, especially if they do not 
have access to adequate information about clinical research, including the language of the 
information. The aim of this study was to describe the context for transparency of clinical 
trials in Croatia in relation to countries in Central and Eastern Europe, and to assess how 
informed Croatian patients are about clinical trials and their accessibility. 
Participants and Methods: We assessed the transparency of clinical trials from the data 
available in the public domain. We also conducted an anonymous survey on a 
convenience sample of 257 patients visiting two family medicine offices or an oncology 
department in south Croatia, and members of national patients’ associations.  
Results: Despite legal provisions for transparency of clinical trials in Croatia, they are 
still not sufficiently visible in the public domain. Among countries from Central and 
EASE Europe, Croatia has the fewest number of registered trials in the EU Clinical Trials 
Registry. 66% of the patients in the survey were aware of the existence of clinical trials 
but only 15% were informed about possibilities of participating in a trial. Although 58% 
of the respondents were willing to try new treatments, only 6% actually participated in a 
clinical trial. Only 2% of the respondents were aware of publicly available trial registries. 
Conclusions: Our study demonstrates that there is low transparency of clinical trials in 
Croatia, and that Croatian patients are not fully aware of clinical trials and the possibilities 
of participating in them, despite reported availability of Internet resources and good 
communication with their physicians. There is a need for active policy measures to 
increase the awareness of and access to clinical trials to patients in Croatia, particularly in 
their own language. 
Key words: access to information; awareness; patient participation; clinical trials; 
registries 
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2. INTRODUCTION 
 
 6 
Transparency is at the heart of health research (1). Transparency and completeness of 
clinical trial reporting is important not only for unbiased assessment of health interventions 
and formulation of health practice guidelines (2), but is also an obligation towards altruistic 
individuals who volunteer for research (3). The increase in the transparency standards for 
clinical trials that we witness today, from the availability of information about the existence of 
trials to the availability of trial results and data, is the outcome of joined effort of journal 
editors, researchers and policy makers to improve the quality of health research and empower 
the patients and their families to get the best treatment available (3-6). 
Despite the increased openness of information of clinical trials, it is still often difficult 
to successfully enrol participants into trials. Although most patients seem to be aware and 
willing to participate in clinical trials (7), only a small fraction of patients who meet the 
requirements actually participate in trials (8). Only 27% of patients discuss clinical trials as an 
option with their physician (9). There is also evidence of gender imbalance in the awareness 
about clinical trials, with male patients reporting more often that they are informed about 
clinical trials (10). 
One of the main reasons why patients take part in clinical trials is the possibility to 
benefit from new treatment (3,11). On the other hand, there are many potential reasons why 
patients avoid entering a clinical trial. These include the fear of being a “human guinea pig”, 
trying something no one knows whether it would work, worries that they will be in the control 
group receiving a placebo and be thus left without help, as well as the feeling that joining a 
clinical trial means that all hope is lost (12). One of the problems contributing to this distrust 
is the lack of understanding of the methodology of clinical trials and their purpose, despite the 
information received during informed consent procedure (11). More active engagement in 
information translation to patients may be beneficial, as studies show that engagement of 
special educators, who spend more time talking face to face with participants, improve 
participants' understanding of specific clinical trial (13). Also, new forms of recruitment 
strategies may bring down some barriers to patient participation in clinical trial (14). 
However, there is also evidence that education interventions related to participation in clinical 
trials may not influence the patients’ motivation for trial accrual (15). 
Patients’ knowledge and awareness of and participation in clinical trials may be a 
special problem for smaller research communities such as Croatia. There is little information 
on how well patients are informed about clinical trials in Croatia (16). Judging from 
experience of low awareness of and adherence to common medical procedures among 
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Croatian patients (17,18), high level of information about participation in clinical trials cannot 
be expected. One of the reasons for the lack of information on clinical trials in Croatia could 
be because the information is not available in the Croatian language. Most of the information 
about clinical trials is available only in English, although some countries have followed the 
recommendations of the World Health Organization (WHO) and established their national 
registries of clinical trials, with information available in the native language (19). 
The aim of our study was to examine the transparency of official information available 
about clinical trials conducted in Croatia in comparison to other countries in Central and East 
Europe, and to explore the awareness and opinions of Croatian patients about clinical trials. 
We targeted general patient population attending family medicine practices as well as patient 
groups with special interest in clinical trials – cancer patients and patients’ associations. 
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3. METHODS 
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Study design 
Data sources. To identify the availability of information on clinical trials in Croatia, 
we searched the web-sites of the Ministry of Health (https://zdravlje.gov.hr/), which is a 
regulatory competent authority for the approval of clinical trials, and the Agency for 
Medicinal Products and Medical Devices (http://www.halmed.hr/en/O-HALMED-u/), which 
hosts the national Central Ethics Committee (CEC). CEC issues opinions in the procedure of 
granting approvals for clinical trials (20). We compared the legislative framework for the 
transparency of clinical trials in Croatia to that for other EU countries from Central and 
Eastern Europe (Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovakia and 
Slovenia) which had similar social and economic history of transition from socialist to market 
economy (21), using the information on the ethics review of clinical trial protocols in Europe 
collected by the European Forum for Good Clinical Practice (20). 
The data on the total number of registered clinical trials were collected from two 
international registers on January 16, 2017: the EU Clinical Trials Register of the European 
Medicines Agency (https://www.clinicaltrialsregister.eu/ctr-search/search), which registers 
interventional clinical trials on medicines conducted in the European Union (EU) and the 
European Economic Area (EEA) since 2004, and ClinicalTrials.gov 
(https://clinicaltrials.gov/ct2/home), which is a registry and results database of clinical studies 
and is hosted by the National Library of Medicine.. 
Patient survey. The survey was performed on a convenient sample during two months 
in 2015/2016. Participation was invited from the following patients’ populations: 1) patients 
with chronic diseases visiting two family medicine offices, one in the city of Split and one on 
the island of Hvar; 2) patients from the Department of Oncology of the University of Split 
Hospital Centre; 3) members of patients’ associations at a national level, via pen-and-paper 
questionnaire or online social media groups. The survey had a single round of data collection, 
with no reminders. The survey was voluntary and anonymous, and was approved by the 
Ethics Committee of University of Split School of Medicine as a part of the research grant 
“Professionalism in Health Care” funded by the Croatian Science Foundation (Grant No. IP-
2014-09-7672). The survey included only adult responders, but they could answer questions 
for their children. 
The survey was constructed as a 20-item questionnaire (Table 1) to collect the 
following information: patients’ basic demographic characteristics; predominant 
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disease/condition and received treatments; relationship with their physician(s); satisfaction 
with the communication with the physician and the treatment received; interest in their 
disease and for seeking additional information about it; awareness of clinical trials and 
participation in them; and willingness to participate in a clinical trial. The questionnaire was 
piloted with four experts to test its face validity; the pilot resulted in minor language changes 
but no changes in the questions. 
Statistical analysis 
Categorical data were presents as percentages or ratios (when N<100) and continuous 
data as medians ± interquartile range. Comparisons were made using chi-square test or 
Fisher’s exact test where expected cell frequency was less than five for categorical data, or 
Kruskal Wallis test with Mann Whitney U test as a post-hoc test for continuous data. 
Statistical analysis was performed using the SPSS version 18 (SPSS Inc., Chicago, IL). The 
significance threshold was set at P<0.05 (for post-hoc tests, Bonferroni adjustment was made 
and significance threshold was set at P<0.01). 
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4. RESULTS 
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Context for trial registration in Croatia 
The conduct of clinical trials in Croatia is governed by several laws and regulations 
(20). Clinical trials, both industry and non-industry sponsored, on drugs and medical devices 
must be approved by the Minister of Health, after positive approval from the national CEC. 
Trials involving other interventions, which are outside of the scope of the CEC, must be 
approved by relevant local ethics committees. There is no national policy on the registration 
of clinical trials before their inception, but there is legal requirement for a register of all 
approved clinical trials since 2010 (20). However, the scope of this register is not yet defined 
and it has not been established, as judged by the information from the web-site of the Ministry 
(January 2017). 
The most recent legal regulation requires that all approved trials should be available 
not only at the web-site of the Ministry of Health but also in the EU Clinical Trial Register 
(22). The documentation on approved clinical trials from 2010 onward is available in the form 
of PDF documents at the Ministry’s web-site (23). The information on a trial consists of the 
official scientific title of the trial in English and Croatian, EU register (EUdraCT) number, 
name of the tested drug, indication (disease), and trial sites (the name of the institution). The 
documents list 50 trials in 2016, 59 in 2015, 55 in 2014, 77 in 2013 and 57 in 2012. The lists 
seem to be have been updated, as some of the trial from earlier years have a notification that 
they had been closed. According to the database from the European Forum for Good Clinical 
Practice from 2012 (20), no information is available on the transparency of clinical trials in 
Bulgaria, Slovakia and Slovenia, while Romania had no policy on the registration of clinical 
trials. Hungary had no national policy on trial registration but required that all trials are 
registered in the EU clinical trial register, EudraCT. Poland has a national register, which is 
not open to the public but permission may be given to interested persons. The Czech Republic 
has an open national register. 
In order to assess the number of past and currently ongoing trials in Croatia and EU 
countries in Central and Eastern Europe, we searched the EU Clinical Trial Register 
(EUCTR) and the ClinicalTrials.gov register (Table 2). At the time of the search (16 January 
2017), EU Clinical Trials Register had 29502 clinical trials with a EudraCT protocol 
conducted in the European Union (EU), or the European Economic Area (EEA) after 1 May 
2004. ClinicalTrials.gov listed 234467 studies with locations in the USA and 195 other 
countries. In comparison to other EU countries from Central and Eastern Europe, which 
joined the EU in 2004 or 2007, Croatia, which joined in 2013, has a smaller number of 
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registered clinical trials in EUCTR (Table 2). Although the percentage of ongoing registered 
studies was similar in all countries from our comparison (around 70% or over), the percentage 
of trials with registered results was the smallest in Croatia: 13% compared to 36-48% in other 
countries (Table 2). The content analysis of 26 trials with results posted for Croatia 
demonstrated that 20 had information only in English, and six had the only the scientific title 
of the trial translated into Croatian, and all other information in English only. In the 
ClinicalTrials.gov, the percentages of open studies or those with registered results were 
similar across all countries, with 12-17% of studies still recruiting and with 21-36% of trials 
having registered results. 
 
Patients’ survey 
During the sampling time-frame, responses from 257 participants were collected 
(Table 3). We could not calculate the response rate due to the open nature of the survey, 
including open call to patients via their respective social media groups. There were 117 men 
(46%) and 137 women (53%), mostly in the 41-80 age group (67%). Patients were treated for 
their major chronic disease or cancer in Split (69%), Zagreb (25%) or Osijek (2%). The 
treatment was mostly received in university hospital centres (67%) and in family medicine 
practices (40%). Patients reported different chronic conditions, and most common diagnosis 
were carcinomas (26%), diabetes (13%) and mental illnesses (12%). Members of a patients’ 
association constituted 21% of the respondents. 
Although 82% participants reported that they felt free to ask their physicians about 
their treatment, 69% of those were actually interested in asking their physician and/or did ask 
(Table 4). Even when they asked, 20% did not understand or did not fully understand the 
information they got from their physician. Although patients reported good communication 
with their physicians, a half of the respondents searched for more information, mostly from 
friends (33%) or the Internet (41%), predominantly using general internet searches rather than 
specialized health sites. Only 2% of the respondents were aware of publicly available trial 
registries, such as ClinicalTrials.gov.  
Although 66% of the respondents were aware of clinical trials, only 15% were 
informed about possibilities of participating in a trial (Table 5). Furthermore, 58% of the 
respondents were willing to try new treatments but only 6% actually participated in a clinical 
trial. Men significantly more often reported being informed about clinical trials than women 
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(63% vs. 37%, P=0.017). 
Survey respondents coming from different patients’ groups significantly differed in 
their answers (Table 6). As expected, patients attending the hospital oncology department 
reported having significantly more annual appointments with the physician(s) than other 
respondent groups (P<0.001). Respondents from the online survey and those from patients’ 
associations reported more often that they were aware of clinical trials in comparison to other 
groups (P<0.001). Online survey respondents also more often reported the willingness to try 
new treatments that the other groups, except the respondents from patients’ organizations 
(P=0.014). 
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5. DISCUSSION 
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Our study showed that Croatian patients were not well informed about possibilities of 
participating in a clinical trial. Although they were reportedly aware of existence of trials, 
they did not take the opportunity to participate in them. Only 12% of the patients reported to 
be informed about clinical trials by their physicians, which is much lower than current 
percentages reported elsewhere in EU, such as 27% in England and Scotland (9). Men in our 
study, similar to the study in the UK (9) more often reported knowledge of clinical trials, 
although women significantly more often used the Internet to search for health information, as 
has been shown for other patient populations (24). 
The results of our survey should be interpreted with caution because of the 
methodological constraints of the convenient survey sample and self-reported nature of the 
answers. The survey was performed in a single university hospital centre and two family 
medicine practices in South Croatia, as well as on a national, albeit small sample of members 
from patients’ organizations, and cannot be fully representative of the whole Croatia. The 
sample may have been biased towards patients treated in larger cities in Croatia, as over 90% 
of the respondents were treated in two largest hospital settings – Zagreb and Split. However, 
this means that the observed low level of engagement in or information on clinical trials in 
such a sample may be an underestimation of the situation at the national level, and may be 
even lower in rural areas. Our study is, to the best of our knowledge, the first published 
survey of patients’ awareness and participation in clinical trials in Croatia, and should be 
taken as the baseline and evidence for any future actions and interventions to increase the 
knowledge and participation in clinical trials. 
The low awareness and participation of patients in clinical trials observed in our study 
may be linked to low transparency of clinical trials in Croatia. Although Croatia has good 
legal provisions for increasing trial transparency, with the requirement for listing of the 
approved trials and the national register (22), neither the listing of approved trial nor the 
register have been fully implemented: the register does not exist and the listings lack 
sufficient information for someone who may be eligible for a trial. For example, only the 
institutions where the trial is performed are listed, without contact details for responsible 
person(s) that could be contacted about trial participation. In contrast, major trial registers, 
like the ClinicalTrials.gov in the USA, have been developed to help individuals with serious 
or life-threatening diseases or conditions and their families to find trials testing new 
interventions, was wells as to help researcher identify most suitable participants for the trials 
(25). The lack of sufficient information on approved trials at the Ministry site is also against 
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the standards of the WHO in regard to the minimum amount of information needed for trial 
registration (26): 1. Primary Registry and Trial Identifying Number, 2. Date of Registration in 
Primary Registry, 3. Secondary Identifying Numbers, 4. Source(s) of Monetary or Material 
Support, 5. Primary Sponsor, 6. Secondary Sponsor(s), 7. Contact for Public Queries, 8. 
Contact for Scientific Queries, 9. Public Title, 10. Scientific Title, 11. Countries of 
Recruitment, 12. Health Condition(s) or Problem(s) Studied, 13. Intervention(s), 14. Key 
Inclusion and Exclusion Criteria, 15. Study Type, 16. Date of First Enrollment, 17. Target 
Sample Size, 18. Recruitment Status, 19. Primary Outcome(s) and 20. Key Secondary 
Outcomes. 
According to our analysis of information on trials available in major international 
registries, Croatian patients can learn most about potentially relevant clinical trial from 
ClinicalTrials.gov then from any other, including the EUCTR. In general, ClinicalTrials.gov 
has more registered studies from the countries analysed in our study than the EUCTR mostly 
because the scope of the two registers is different and the US register is older than the 
EUCTR (5,6). EUCTR, which Croatia officially joined in 2013, still has the fewest number of 
registered trials from Croatia, especially those with already available results. Unfortunately, 
almost all of the information in EUCTR is not in Croatian, and all information in the 
ClinicalTrials.gov is in English. 
In conclusion, despite increased transparency of clinical trials worldwide, Croatian 
patients still have limited access to full information about clinical trials performed in Croatia, 
particularly in their own language and have low awareness about clinical trials and the 
possibilities of participating in them is rather low, despite reported availability of Internet 
resources and good communication with their physicians. The first step in increasing this 
transparency for the benefit of the patients would be to fully implement legal provisions that 
have existed for more than five years (20). Only when the basic information about clinical 
trials is full, transparent and easily accessible, preferably in native language, efforts could be 
focused on managing the communication with patients (14), with physicians and other health 
workers to support participation in clinical trials and clear insecurities with participants (27). 
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Table 1. Survey questionnaire 
1. 1 General information: Age (number)*:    Gender  female  male 
2.  The main disease you are suffering from:  
3. 2 Are you a member of any patients' association (mark the answer)? If the answer is yes, which one? 
NO YES Patients' association:  
4. 2 City where you are seeing the specialist physician who treats you from your main disease (you can mark multiple 
answers): 
a) Zagreb 
b) Split 
c) Rijeka 
d) Osijek 
e) Other (which one): 
5. 3 Type of institution where you are getting your treatment (you can mark multiple answers): 
a) University hospital centre 
b) Hospital 
c) Health centre  
d) Family medicine offices  
e) Private specialist physician  
f) Other (what type):  
6. 4 How often do you see your specialist physician who treats you from your main disease (the average number of visits per 
year)?  
7. 5 Does your specialist physician discuss your therapy with you?  
No Yes  Yes, but not clearly 
If you are not satisfied with communication with your physician, please describe a problem:  
8. 6 Does your specialist physician answers clearly to your questions? 
No Yes  Yes, but not clearly 
If you are not satisfied with communication with your physician, pleas describe a problem:  
9. 7 Do you feel free to ask your specialist physician if there is any therapy that would be better for you and your treatment?  
YES  NO 
Write any comments, if you wish. 
10. 8 Do you ever seek information about your diagnosis or treatment elsewhere?  YES        NO 
11. 9 If you do seek information on your diagnosis or treatment, what do you use? You can mark multiple answers. 
a) books 
b) friends (including friends who are health professionals) 
c) research articles 
d) pharmaceutical promotional materials 
e) Internet 
f) medical lay journals 
g) other source of information: 
12. 1 Are you willing to try some new, potentially better, types of therapy for your disease that are current or being 
investigated? YES  NO 
13. 1 Have you ever been informed about possibility to participate in a trials that are investigating new ways of treating your 
disease? YES  NO 
14. 1 If the answer to previous question is yes, who informed you (you can mark multiple answers)? 
a) physician 
b) pharmacist 
c) family member/friend 
d) patients’ association where you are the member 
e) Someone else (who?):  
15. 1 Have you ever heard of clinical trials or experiments?  YES  NO 
16. 1 If you have heard of clinical trials, please describe what they mean for you.  
17. 1 Do you have Internet access (at home, at work or any other place)?   YES  NO 
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18. 1 If you are searching online for possibilities to participate in a clinical trial, which sources of information do you use (you 
can mark multiple answers)?  
a) internet search engine (Google and similar) 
b) www.zdravlje.hr 
c) www.clinicaltrials.gov 
d) www.trialscentral.org 
e) something else (which one):  
19. 1 Have you ever participated in a clinical trial?   YES NO 
20. 1 If you have participated in a clinical trial, pleas describe your experience:  
*The online version of the survey had categories for age: 0-17, 18-40, 41-65, 66-80, and >80 
years. 
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Table 2. Clinical trials from EU countries in Eastern and Central Europe registered in 
international trial registries* 
 EU Clinical Trials Register ClinicalTrials.gov 
Country Total Opened 
(%)† 
With 
registered 
results (%) 
Total Opened 
(%)† 
With 
registered 
results (%) 
Bulgaria 1289 868 (67) 610 (47) 1430 240 (17) 424 (30) 
Croatia 196 174 (89) 26 (13) 772 130 (17) 225 (29) 
Czech Rep. 3340 2421 (72) 1606 (48) 3304 545 (16) 969 (29) 
Hungary 3414 2473 (72) 1612 (47) 3028 506 (17) 929 (31) 
Poland 1771 1258 (71) 630 (36) 4794 766 (16) 1367 (29) 
Romania 195 168 (86) 70 (36) 1969 294 (15) 681 (35) 
Slovakia 885 625 (71) 398 (45) 1362 167 (12) 495 (36) 
Slovenia 293 223 (76) 137 (47) 482 84 (17) 101 (21) 
*Search performed on 16 January 2017. 
†EU Clinical Trials Register: filtered as “Ongoing” for Trial Status in Advanced Search; 
ClinicalTrials.gov: filtered as “Open Studies” for Recruitment in Advanced Search. 
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Table 3. Descriptive statistics of the study sample (N=257) 
Characteristics No. (%)* 
Gender (N, %) 
Female 137 (53) 
Age group in years (N, %)†: 
0-17 10 (4) 
18-40 49 (19) 
41-65 92 (36) 
66-80 81 (32) 
≥81 9 (4) 
Main disease (N, %)‡: 
Cancer/tumour 66 (26) 
Mental illness 31 (12) 
Diabetes 33 (13) 
Hypertension 18 (7) 
Heart conditions 16 (6) 
Pulmonary diseases 7 (3) 
Spine and bones diseases 16 (6) 
Other diseases 46 (18) 
Patients’ association membership (N, %) 53 (21) 
Place of treatment (N, %): 
Zagreb 64 (25) 
Split 177 (69) 
Osijek 6 (2) 
Institution of treatment (N, %)‡: 
University Hospital Centre 173 (67) 
Hospital 36 (14) 
Health centre 12 (5) 
Family medicine offices 103 (40) 
Private specialist physician 22 (9) 
*Percentages are to the total sample, to indicate missing responses. 
†Children were not recruited for the study, but parents could answer the survey about the 
experiences in the treatment of their children. 
‡Percentages do not add up because multiple choices were possible. 
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Table 4. Patient’s satisfaction and interest about their disease and treatment* 
 Total (No., %) 
(N=257) 
Men (No., %) 
(N=117) 
Women (No., 
%) (N=137) 
P† 
Feels free to ask physician 
about the treatment 
211 (82) 100 (48) 110 (52) 0.190 
Discusses therapy with physician: 
Yes 177 (69) 77 (44) 100 (57) 
0.519 Yes, but nor clearly 37 (14) 18 (50) 18 (50) 
No 29 (11) 15 (54) 13 (4) 
Physician answers to patient’s question: 
Yes 195 (76) 90 (46) 105 (54) 
0.414 Yes, but not clearly 35 (14) 13 (39) 20 (61) 
No 15 (6) 9 (60) 6 (40) 
Seeks for information about 
disease and treatment 
elsewhere: 
133 (52) 60 (46) 71 (54) 0.538 
Source of information seeked 
elsewhere (multiple responses 
allowed): 
    
In books 53 (21) 22 (42) 30 (58) 0.147 
Friends (including friends 
who are health 
professionals) 
84 (33) 39 (48) 43 (52) 0.377 
Research articles 36 (14) 13 (36) 23 (64) 0.055 
Pharmaceutical promotional 
materials 
12 (5) 4 (33) 8 (67) 0.372‡ 
Online 105 (41) 43 (41) 61 (59) 0.010 
Medical lay journals 19 (7) 6 (32) 13 (68) 0.080 
Online searching tools used: 
Internet search engine 
(Google or similar) 
107 (42) 44 (42) 62 (59) 0.251 
www.zdravlje.hr 24 (9) 12 (50) 12 (50) 0.317 
www.clinicaltrials.gov 6 (2) 1 (17) 5 (83) 0.232‡ 
*The numbers for men and women do not always add because of missing data. The numbers in 
brackets for man and women are row percentages, and numbers in brackets for the Total are the 
percentage of all respondents. 
†Chi-square test. 
‡Fisher’s exact test. 
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Table 5. Patient’s awareness of clinical trials* 
 Total (No., %) 
(N=257) 
Men (No., %) 
(N=117) 
Women (No., %) 
(N=137) 
P† 
Aware of clinical trials 169 (66) 80 (48) 88 (52) 0.425 
Informed about possible 
participation in clinical trials 
38 (15) 24 (63) 14 (37) 0.017 
Informed about possible 
participation in clinical trials by: 
    
Physician 31 (12) 20 (65) 11 (36) 0.316 
Pharmacist 6 (2) 3 (50) 3 (50) 0.669‡ 
Family member/friend  10 (4) 4 (40) 6 (60) 0.156‡ 
Patients’ association 6 (2) 5 (83) 1 (17) 0.378‡ 
Willingness to try new 
treatments 
149 (58) 74 (50) 74 (50) 0.147 
Participated in clinical trials 15 (6) 8 (53) 7 (47) 0.338 
*The numbers for men and women do not always add because of missing data. The numbers in 
brackets for man and women are row percentages, and numbers in brackets for the Total are 
percentage of all respondents. 
†Chi-square test. 
‡Fisher’s exact test. 
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Table 6. Patients’ responses according to the place of survey* 
 City family 
medicine 
office 
(N=87) 
Island 
family 
medicine 
office 
(N=31) 
Hospital 
oncology 
department 
(N=52) 
Patients’ 
associations 
(N=55) 
On-
line 
patient 
survey 
(N=32) 
P† 
Gender (No.)       
Male 42/87 14/30 22/52 23/55 16/30 0.825 
Female 45/87 16/30 30/52  32/55 14/30 
No. of appointments 
with physician per 
year (median, IQR) 
2 (3) 2 (2) 13.5 (20) 3 (3) 3.5 (3) <0.001‡ 
Seeks for information 
about disease and 
treatment elsewhere 
(No.) 
38/81 19/31 26/51 30/54 20/29 0.272 
Willingness to try 
new treatments (No.) 
46/79 13/29 32/46 33/55 25/29 0.014§ 
Awareness of clinical 
trials (No.) 
43/85 17/30 35/48 46/53 28/29 <0.001# 
Informed about 
possible participation 
in clinical trials (No.) 
13/81 3/29 7/50 12/54 3/29 0.598 
Participated in clinical 
trials (No.) 
5/82 1/31 0/50 7/53 2/29 0.060 
*Data as presented as the number of responses/total responses for the question. 
†Chi-square test or Fisher’s exact test for comparisons including cell frequencies less than five. 
Bonferroni adjustment for all post hoc analysis was set to the significance threshold of P=0.01. 
‡Kruskal-Wallis test and post-hoc analysis (Mann Whitney U test): Hospital oncology 
department group vs all other survey places (P<0.001). 
§Post-hoc analysis: Online-patient survey group vs Island family practice group (P=0.001), City 
family medicine office group (P=0.007) and Patients’ association group (P=0.014). 
# Post-hoc analysis: City family medicine office group vs Patients’ association group 
(P<0.001); Hospital oncology department group (P=0.012) and On-line patient survey group 
(P<0.001); Island family medicine office vs Patients’ association group (P=0.002) and On-line 
patient survey group (P<0.001); Hospital oncology department group vs On-line patient survey 
group (P=0.009). 
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